Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430079 · ClinicalTrials.gov registry record · NA
Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma
A NA study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- NA
- Development phase
- 48
- Enrollment target
NCT00430079: Clinical Trial NA study, sponsored by National Cancer Institute (NCI).
NCT00430079 is a NA study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00430079, a NA study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
Study Summary
This clinical trial is using EF5 to measure the oxygen level in tumor cells of patients undergoing surgery or surgery biopsy for newly diagnosed supratentorial malignant glioma. Diagnostic procedures using the drug EF5 to measure the oxygen level in tumor cells may help in planning cancer treatment
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- PROCEDURE conventional surgery
- DRUG etanidazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2001-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00430079
The ClinicalTrials.gov registry entry for NCT00430079 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00430079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00430079 about?
NCT00430079 is a clinical study titled "Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma". This clinical trial is using EF5 to measure the oxygen level in tumor cells of patients undergoing surgery or surgery biopsy for newly diagnosed supratentorial malignant glioma. Diagnostic procedures using the drug EF5 to measure the oxygen level in tumor cells may help in planning cancer treatment
What is the current status of trial NCT00430079?
This trial is currently terminated. It is a NA study. The enrollment target is 48 participants. The study started on 2001-07.
What interventions are being tested in trial NCT00430079?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), conventional surgery (PROCEDURE), etanidazole (DRUG).
Who is sponsoring clinical trial NCT00430079?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.